Source: Annual Congress 2010 - Pulmonary vascular diseases
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Karaman, M. Karaman, E. S. Ucan, N. Gokmen, D. Gurel, C. Coker, Y. Adali, O. Yilmaz (Izmir, Turkey). Bevacizumab administration in monocrotaline induced pulmonary arterial hypertension rat model. Eur Respir J 2010; 36: Suppl. 54, 4489

Member's Comments

No comment yet.

Related content which might interest you: Bevacizumab administration in pulmonary arterial hypertension rat model decondary to chronical hypoxia exposure Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Reversibility of the monocrotaline pulmonary hypertension rat model Source: Eur Respir J 2013; 42: 553-556 Year: 2013 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Two rat models of hemolysis-induced pulmonary hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 The effect of montelukast on the monocrotaline induced pulmonary disease in the wistar rat Source: Eur Respir J 2004; 24: Suppl. 48, 561s Year: 2004 Pirfenidone protects against pulmonary hypertension in the Sugen5416/hypoxia rat model Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018 Effect of roflumilast on hypoxia- and monocrotaline-induced pulmonary hypertension in rats Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair Year: 2007 Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats Source: Eur Respir J 2011; 37: 813-822 Year: 2011 The effect of 6-mercaptopurine treatment on experimentally induced pulmonary arterial hypertension Source: International Congress 2017 – New perspectives from experimental models of pulmonary hypertension Year: 2017 The effect of acetazolamide on pulmonary hypertension induced by chronic hypoxia in rats Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008 Enhanced efficacy of combining imatinib with sildenafil in a rodent model of pulmonary arterial hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil Source: Eur Respir J 2010; 36: 800-807 Year: 2010 TRAM-34 ameliorates hypoxia-induced pulmonary arterial hypertension in rats Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Bosentan fails to prevent the development of pulmonary arterial hypertension in athymic rats exposed to chronic hypoxia Source: Annual Congress 2010 - Pulmonary vascular diseases Year: 2010 Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006 Inflammatory changes in a murine model of monocrotaline-induced pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 365s Year: 2005 Effect of zamicastat, a dopamine beta-hydroxylase inhibitor, on the monocrotaline rat model of pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Early atorvastatin administration suppresses the oxygen-activating ability of rat neutrophils during monocrotalinin-induced pulmonary arterial hypertension (PAH). Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Effects of BMPR-II signal transduction in the pulmonary vascular remodeling of monocrotaline induced pulmonary hypertension in rats Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension Year: 2008 A novel murine model of severe pulmonary arterial hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010